en.aazsante.fr

The Largest Portal Of Health And Quality Of Life.

Anvisa approves new medicine for hepatitis C

Anvisa approves new medicine for hepatitis C

The National Agency of Sanitary Surveillance (Anvisa) approved the registration of a new medicine for the treatment of Hepatitis C. The approval was published in the Official Gazette (DOU) , according to Anvisa, Maviret (glecaprevir / pibrentasvir) will be marketed in the form of a coated tablet with a concentration of 100mg and 40mg. The product is indicated for the treatment of Hepatitis C (genotypes 1, 2, 3, 4, 5 and 6) in patients with and without cirrhosis.

Maviret will be manufactured by Fournier Laboratories Ireland Ltd., and the holder of the drug registration in Brazil is Abbvie Farmacêutica Ltda.

How to treat Hepatitis C?

There is not always a need for treatment. The doctor will know if your case will require therapy or not. Usually, even for people who do not get treatment, follow-up blood tests are requested.

Other cases, however, will require treatment to avoid further complications. In these situations, hepatitis C infection is treated with a combination of antiviral drugs to be taken over several weeks, which aims to eliminate the virus from the patient's body.

Learn more about treatment for disease here!

Living with

If you have been diagnosed with hepatitis C, your doctor will probably recommend some lifestyle changes. These measures will help to keep you healthy, such as:

Stop drinking alcohol, which speeds up the progression of liver disease